ALX Oncology Announces September Investor Conference Participation
31 August 2023 - 9:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that management
will participate in two upcoming investor conferences.
H.C. Wainwright
25th Annual Global Investment
ConferenceFormat: Fireside chat with analyst, Swayampakula
Ramakanth Date: Monday, September 11Time: 2:30 PM Eastern
TimeLocation: New York, NY Webcast link: Available here
2023 Cantor Global Healthcare
ConferenceFormat: Fireside chat with analyst, Li
WatsekDate: Tuesday, September 26Time: 9:10 AM Eastern
TimeLocation: New York, NY Webcast link: Available here
The live webcasts for the H.C. Wainwright and
Cantor fireside chats can be accessed by visiting the Investors
section of ALX Oncology’s website at www.alxoncology.com and
selecting Events under the News and Events tab. A replay
of the webcast will be archived for up to 90 days following the
fireside chat date.
About ALX Oncology
ALX Oncology is a publicly traded,
clinical-stage immuno-oncology company focused on helping patients
fight cancer by developing therapies that block the CD47 immune
checkpoint inhibitor and bridge the innate and adaptive immune
system. ALX Oncology’s lead product candidate, evorpacept, is a
next generation CD47 blocking therapeutic that combines a
high-affinity CD47 binding domain with an inactivated, proprietary
Fc domain. Evorpacept has demonstrated promising clinical responses
across a range of hematologic and solid malignancies in combination
with a number of leading anti-cancer antibodies. ALX Oncology is
currently focusing on combining evorpacept with anti-cancer
antibodies (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors.
Evorpacept’s Rational Design and Dual
Development Pillars
Rationally engineered with an inactive Fc
effector function, evorpacept’s clinical data to date has
demonstrated a substantially improved safety profile over other
anti-CD47 molecules in the clinic with an active Fc (i.e., binding
the Fc gamma receptor on macrophages). This superior safety profile
allows higher dosing with minimal overlapping toxicity in the
combination treatment setting. CD47 expressed on cancer cells binds
to its receptor SIRP alpha, which is predominantly expressed on two
cell types: macrophages and dendritic cells. ALX Oncology is
focusing evorpacept development with the standard-of-care agents as
originally designed revolving around these two cell types,
including:
Anti-cancer
antibodies (the “don’t eat me”
signal): evorpacept enables Fc-mediated
antibody-dependent phagocytosis by macrophages in combination with
anti-cancer antibodies (e.g., Herceptin®) with an active Fc domain,
which is otherwise impaired by CD47 expression on cancer cells
binding to SIRP alpha on macrophages. This same mechanism of action
applies to ADCs.
PD-1/PD-L1
immune checkpoint inhibitors (the “don’t activate
T-cells” signal): evorpacept enables T-cell
activation by dendritic cells that are constitutively inhibited by
CD47 expression on cancer cells binding to SIRP alpha on dendritic
cells. Activated dendritic cells present neoantigens to T-cells
that once activated will kill cancer cells when the PD-1/PD-L1
inhibitory interaction is blocked by T-cell checkpoint
inhibitors.
Investor Contacts:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
mchatterjee@bplifescience.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Apr 2024 to May 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From May 2023 to May 2024